CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1B | Calcium channel, voltage-dependent, N type, alpha 1B subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1E | Calcium channel, voltage-dependent, R type, alpha 1E subunit | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA1F | Calcium channel, voltage-dependent, L type, alpha 1F subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
CACNA1G | Calcium channel, voltage-dependent, T type, alpha 1G subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1H | Calcium channel, voltage-dependent, T type, alpha 1H subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1I | Calcium channel, voltage-dependent, T type, alpha 1I subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CATSPER2 | Cation channel, sperm associated 2 | Disease related genes Plasma proteins Potential drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CATSPER4 | Cation channel, sperm associated 4 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
CNGA1 | Cyclic nucleotide gated channel alpha 1 | Disease related genes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
CNGA2 | Cyclic nucleotide gated channel alpha 2 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
CNGA3 | Cyclic nucleotide gated channel alpha 3 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
CNGA4 | Cyclic nucleotide gated channel alpha 4 | Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
CNGB3 | Cyclic nucleotide gated channel beta 3 | Disease related genes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
GALNT8 | Polypeptide N-acetylgalactosaminyltransferase 8 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
HCN1 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 1 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
HCN2 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
HCN3 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 3 | Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
HCN4 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA4 | Potassium voltage-gated channel, shaker-related subfamily, member 4 | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA6 | Potassium voltage-gated channel, shaker-related subfamily, member 6 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA7 | Potassium voltage-gated channel, shaker-related subfamily, member 7 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNB2 | Potassium voltage-gated channel, Shab-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNC4 | Potassium voltage-gated channel, Shaw-related subfamily, member 4 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCND1 | Potassium voltage-gated channel, Shal-related subfamily, member 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNG1 | Potassium voltage-gated channel, subfamily G, member 1 | Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNG2 | Potassium voltage-gated channel, subfamily G, member 2 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNG3 | Potassium voltage-gated channel, subfamily G, member 3 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNG4 | Potassium voltage-gated channel, subfamily G, member 4 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH3 | Potassium voltage-gated channel, subfamily H (eag-related), member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNH4 | Potassium voltage-gated channel, subfamily H (eag-related), member 4 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH5 | Potassium voltage-gated channel, subfamily H (eag-related), member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |